#United States #Austin #gene therapy #Genprex #diabetes

Genprex Advances Diabetes Gene Therapy Program

Genprex, Inc., a clinical-stage gene therapy company listed on NASDAQ under the ticker GNPX, is making significant strides in its efforts to develop innovative gene therapies aimed at treating diabetes, specifically Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D). Recently, the company announced an important update on its diabetes gene therapy program, which includes a strategic collaboration with the University of Pittsburgh and the formation of a wholly-owned subsidiary.

New Exclusive License Agreement

A breakthrough in Genprex's diabetes endeavors is the amendment and consolidation of its existing license agreements with the University of Pittsburgh. The new exclusive license grants Genprex worldwide rights to various patented technologies that are crucial for developing gene therapies for both T1D and T2D. These technologies leverage the genes of the Pdx1 and MafA transcription factors, which are controlled by specific promoters related to insulin and glucagon.

Ryan Confer, President and CEO of Genprex, expressed enthusiasm about the advancements in their diabetes program, especially regarding the synergized collaboration with the renowned institution. The updated agreement means Genprex now holds exclusive rights to a robust panel of gene therapies—an advancement that officials believe has the potential to significantly change the diabetes treatment landscape.

Formation of Convergen Biotech

To further expedite the development of its diabetes program, Genprex has created a subsidiary named Convergen Biotech, Inc. This strategic decision aims to separate the diabetes program from the oncology initiatives, allowing for more focused development and potential investment opportunities. The establishment of Convergen Biotech illustrates Genprex's commitment to refining its operational strategies and enhancing the effectiveness of both organizations.

Insights into the Gene Therapy Approach

Genprex's gene therapy for diabetes revolves around administering an adeno-associated virus (AAV), which carries the Pdx1 and MafA genes directly into the pancreatic duct. Remarkably, GPX-002, the company’s gene therapy candidate, aims to facilitate the transformation of alpha cells into functional beta-like cells capable of producing insulin. This approach is not only innovative but holds the promise of offering long-term results for diabetes patients worldwide.

In the case of T1D, GPX-002's design allows it to potentially evade the immune system, while for T2D, the focus is on rejuvenating exhausted beta cells to restore normal insulin production. Such technologies developed under the leadership of Professor George Gittes at the University of Pittsburgh show great promise in advancing diabetes treatments, with ongoing preclinical evaluations underway.

Addressing the Diabetes Epidemic

Diabetes continues to be a major public health concern. Current estimates from the U.S. Centers for Disease Control and Prevention indicate that around 38.4 million Americans have diabetes, with projections indicating a global diabetic population of approximately 783 million by 2045. Both T1D and T2D cause significant health repercussions and economic burdens, costing international healthcare systems billions annually.

Genprex's advancements in diabetes gene therapy represent a beacon of hope amidst these concerning statistics. The company's plans to seek FDA guidance for preclinical studies indicate a clear pathway toward human clinical trials, illustrating their intent to bring transformative treatments to market within the next few years.

Conclusion

Genprex, Inc. stands at the forefront of a revolutionary approach in treating diabetes through gene therapy. With a newly consolidated licensing agreement with the University of Pittsburgh, a dedicated subsidiary for focused development, and innovative technology-based strategies, the company is poised to make significant contributions to diabetes care.

As the world grapples with rising diabetes prevalence, the advancements from Genprex could herald a new era in the effective management and potential reversal of this chronic condition. Investors and health stakeholders are encouraged to stay updated as Genprex continues its journey towards transforming diabetes treatment options.